Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24394305 | 1.00 | USP2 (0.55) | USP2SMN1; SMN2RECQLEPHX2CCR2 | |
| SCHEMBL4235077 | 0.91 | USP2 (0.63) | USP2SMN1; SMN2RECQLEPHX2CCR2 | |
| SCHEMBL2959763 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2RECQLEPHX2ALDH1A1 | |
| SCHEMBL519969 | 0.81 | USP2 (0.66) | USP2SMN1; SMN2RECQLEPHX2CCR2 | |
| SCHEMBL24394304 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2RECQLEPHX2CCR2 | |
| SCHEMBL29503576 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2RECQLEPHX2CCR2 | |
| SCHEMBL5376238 | 0.79 | USP2 (0.58) | USP2SMN1; SMN2RECQLEPHX2HPGD | |
| SCHEMBL18641236 | 0.78 | HPGD (0.49) | USP2SMN1; SMN2RECQLEPHX2ALDH1A1 | |
| SCHEMBL14306574 | 0.77 | USP2 (0.56) | USP2SMN1; SMN2RECQLEPHX2CCR2 | |
| SCHEMBL994310 | 0.77 | USP2 (0.56) | USP2SMN1; SMN2RECQLEPHX2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211119-B1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12570640-B2 | 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4211119-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022051337-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570640-B2 | 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, CLK2 | USP2 3785/4885SMN1; SMN2 689/4885RECQL 483/4885 |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | USP2 3313/4885SMN1; SMN2 676/4885RECQL 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.